Andrea James
Chief Financial Officer
Replay available
Insight Molecular Diagnostics Inc. (IMDX) Q2 2026 Earnings Call
Insight Molecular Diagnostics Inc. (NASDAQ: IMDX) Q2 2026 earnings conference call, held 2026-08-10. Replay captured from the company's public earnings webcast.
Hosted by
Featured presenters
Josh Riggs
Chief Executive Officer
Dr. Ekke Schutz
Chief Scientific Officer
Mason Carrico
Analyst, Stevens & Co.
Mark Massaro
Analyst, BTIG
Thomas Flatton
Analyst, Lake Street
Mike Mattson
Analyst, Needham & Company
Investor webinar replay
Watch the replay and follow the connected company analysis, news, and investor updates for Insight Molecular Diagnostics Inc..
Replay transcript excerpt
WEBVTT 00:00:00.051 -- 00:00:03.872 Thank you for joining us today. 00:00:27.263 -- 00:00:30.813 We also have our analysts with us as panelists. 00:00:30.813 -- 00:00:34.702 After our prepared remarks, our analysts may ask questions. 00:00:34.702 -- 00:00:39.226 Before turning the call over to Josh Riggs, I'd like to review our safe harbor. 00:00:39.226 -- 00:00:44.150 The company will make projections and forward looking statements regarding future events. 00:00:44.150 -- 00:00:48.794 Any statements that are not historical facts are forward looking statements. 00:00:48.794 -- 00:00:54.559 These statements are made pursuant to and within the meaning of the safe harbor provisions 00:00:54.559 -- 00:00:59.141 of the Private Securities Litigation Reform Act of 1995. 00:00:59.221 -- 00:01:04.186 We encourage you to review the company's SEC filings, including the company's most recent 00:01:04.186 -- 00:01:09.351 Form 10-K and subsequent Form 10-Q, which identify risks and 00:01:09.351 -- 00:01:15.116 uncertainties that may cause future actual results or events to differ materially. 00:01:15.116 -- 00:01:21.000 Please note, the forward-looking statements made during today's call speak only to the 00:01:21.000 -- 00:01:26.023 date they are made and Insight Molecular Diagnostics undertakes no obligation to update 00:01:26.023 -- 00:01:30.566 them. And with that, I would like to now turn the call over to Josh Riggs. 00:01:30.566 -- 00:01:32.267 Thanks, Cathy. 00:01:32.267 -- 00:01:36.390 It feels great to be coming to you today with line of sight on expected FDA marketing 00:01:36.390 -- 00:01:41.533 authorization for Graft Assured DX. We have three brief but promising takeaways 00:01:41.533 -- 00:01:46.616 today in our shareholder letter. The first is that after three years...